GLP-1 Strategy - Prime Therapeutics
Develop a holistic GLP-1 strategy
An evidence-based approach to GLP-1 drugs helps you implement custom strategies that promote clinically appropriate use and consider affordability, long-term value and member health outcomes.
92%
Ninety-two percent of people who newly started glucagon-like peptide-1 (GLP-1) agonist drugs for weight loss were no longer taking the drug after three years.
The evolution of GLP-1s
When we look at historical utilization and spend patterns, we forecast that increasing GLP-1 use for weight loss by just 1% of an insured population would drive more than an additional $10 in costs PMPM, totaling 5% of a self-insured employer’s drug spend. So it’s clear that having a strong GLP-1 strategy is an essential element of a successful pharmacy benefits program.
Prime’s GLP-1 real-world research
Year-3 adherence and persistence data
Prime Therapeutics’ leading research shows 1 in 12 remain on a GLP-1 drug for obesity at three years. Findings also show improved persistence with high-potency, obesity-approved GLP-1 products.
Year-3 adherence and persistence research abstract
Learn more about the methodology of Prime’s research study, “GLP-1 Therapy to Treat Obesity Among Members Without Diabetes: Three-Year Persistence and Year-Over-Year Persistence Rate Change.”
Historical
Adherence and persistence data
Prime’s real-world, integrated data revealed further insights at Year 2, including that just 1 in 7 people remain on GLP-1 drugs for weight loss.
Adherence and persistence research abstract
Learn more about the methodology of Prime’s research study, “Year-Two Real-World Analysis of Glucagon-Like Peptide-1 Agonist (GLP-1) Obesity Treatment Adherence and Persistency.”
Cost-of-care data
Individuals without diabetes who started a GLP-1 medication for obesity experienced an average of $4,206 higher cost of care in their second year compared to similar members who did not take a GLP-1 drug for obesity.
Cost-of-care research abstract
Learn more about the methodology of Prime’s research study, “Real-World Analysis of Glucagon Like Peptide-1 (GLP-1) Agonist Obesity Treatment Year-Two Clinical and Cost Outcomes.”
Persistence, adherence and cost-of-care data
Demand for GLP-1 drugs for weight loss continues to increase, and data shows low adherence and increased cost in the first year.
Research abstract
A paragraph is a self-contained unit of a discourse in writing dealing with a particular point or idea. Paragraphs are usually an expected part of formal writing, used to organize longer prose.
Pharmacy Friends
Pharmacy Friends is a podcast dedicated to bringing industry experts to the same table to talk about what is happening in pharmacy today, what is coming in the future and, most importantly, what it means to you. Listen to our episodes that focus on the hot topic of GLP-1s and chronic weight management.
Holistic solutions for weight management
More than 73.1% of adults in the United States are either overweight or obese. In addition to the health impact, obesity costs the health care system almost $173B per year. Prime’s clinical insights report outlines where we are today and how things are shaping up for the future, demystifying trends like GLP-1s and supporting a whole-person approach to sustainable weight management.
Next-level cardiometabolic support
Conditions like obesity, diabetes, hypertension and high cholesterol can compound if left unchecked, causing serious and costly health problems. KeepWell™ offers a personalized and effective path to wellness for your members, driving better outcomes across the cardiometabolic spectrum.
Login Portals
Compliance / Legal
Company
© 2025 Prime Therapeutics LLC